University of Missouri Health Sciences Center, Department of Medicine, Columbia, MO 65212, USA.
Expert Opin Biol Ther. 2012 Feb;12(2):223-33. doi: 10.1517/14712598.2012.646984. Epub 2011 Dec 21.
Pathological antibody production by B lymphocytes is characteristic of numerous primary and secondary glomerular diseases of the kidney. Specific and less toxic therapies that target antibody-producing B cells are therefore needed. Based on its property of selectively depleting CD20(+) B cells, rituximab is a therapeutic option for antibody-mediated kidney diseases and adds to the existing drug armamentarium for the treatment of a number of these disorders.
This article reviews the current use of rituximab in renal disease and transplantation, and includes discussion of the drug's potential role in conditions where traditional treatment has failed. A literature search using PubMed data base was undertaken using search words rituximab and kidney transplantation, glomerulonephritis, antibody production etc.
Rituximab could be a beneficial drug in certain renal diseases and for complications related to kidney transplantation where conventional treatment has not been successful.
B 淋巴细胞产生的病理性抗体是许多原发性和继发性肾小球肾脏疾病的特征。因此，需要针对产生抗体的 B 细胞的特异性和毒性较低的治疗方法。基于其选择性耗竭 CD20(+)B 细胞的特性，利妥昔单抗是治疗抗体介导的肾脏疾病的一种选择，并为治疗许多此类疾病的现有药物武器库增加了一种药物。
本文综述了利妥昔单抗在肾脏疾病和移植中的应用，并讨论了该药在传统治疗失败的情况下在某些疾病中的潜在作用。使用 PubMed 数据库进行了文献检索，使用的检索词包括利妥昔单抗和肾移植、肾小球肾炎、抗体产生等。
利妥昔单抗在某些肾脏疾病和与肾移植相关的并发症中可能是一种有益的药物，对于传统治疗不成功的情况尤其如此。
